REGISTER LOGIN

Lawyers Fatma Sevde Tan

Fatma Sevde Tan

Fatma Sevde Tan

Gün + Partners
[email protected]
BIOGRAPHY
INSIGHTS

Practice Areas & Work Department

Life Sciences

Intellectual Property

Patent and Utility Models


Languages

English

Turkish


Memberships

Istanbul Bar Association

What Will Be the Fate of the Guarantee Provided for the Preliminary Injunction Decision?

Is the Guarantee Provided for the Preliminary Injunction a Part of the Later Compensation Action Arising from the Unfair Preliminary Injunction?
Selin Sinem Erciyas
Aysel Korkmaz Yatkın
Fatma Sevde Tan
14.06.2024

Türkiye's Update: Key Changes in Named Patient Program

Pharmaceuticals that are not authorized in Türkiye or authorized but not available on the market shall be procured from abroad as per a special authorization and on a case by case basis (Named Patient Program-NPP).
Dicle Doğan
Fatma Sevde Tan
22.05.2024

Türkiye İlaç ve Tıbbi Cihaz Kurumu Tıbbi Cihaz Sektör Belgesi Yayınlandı

Türkiye İlaç ve Tıbbi Cihaz Kurumu (“TİTCK”) tarafından tıbbi cihaz sektöründeki son yıllardaki gelişmeler ile birlikte pazarın mevcut durumunu ortaya koymak üzere hazırlanan Tıbbi Cihaz Sektör Belgesi 4 Nisan 2024 tarihinde TİTCK internet sitesinde yayınlanmıştır.
Dicle Doğan
Fatma Sevde Tan
25.04.2024

Turkish Medicines and Medical Devices Agency Published the Industry Report on Medical Devices

On April 4, 2024, the Industry Report on Medical Devices, prepared by the Turkish Medicines and Medical Devices Agency ("Agency") to present the current state of the market together with recent developments in the medical device industry, was published on the Agency’s website.
Dicle Doğan
Fatma Sevde Tan
22.04.2024

Named Patient Program in Turkey - 2024

Named Patient Program (“NPP”) is one of the exceptional pharmaceutical importation regimes for products that are not authorized or authorized but unavailable in the Turkish market for various reasons.
Dicle Doğan
Fatma Sevde Tan
18.03.2024

Yurt Dışından İlaç Temini Usulünde Yapılan Son Değişiklikler

Türkiye’de ruhsatlandırılmamış veya ruhsatlı olmakla birlikte piyasada bulunmayan ilaçlara hastaların ihtiyaç duyduğu durumlarda; söz konusu ilaç, özel izinle yurt dışından ilaç temini olarak adlandırılan istisnai ithalat rejimi ile ülkemizdeki hastalara tedarik edilebilmektedir.
Dicle Doğan
Fatma Sevde Tan
27.12.2023

Recent Changes in the Named Patient Program

Pharmaceuticals not authorized in Turkey or authorized pharmaceuticals not available in the market, shall be procured from abroad as per a special authorization (named patient program) in cases where patients require such pharmaceuticals. While this exceptional import regime for pharmaceuticals was until recently regulated by the Medicines and Medical Devices Agency ("Agency") through guideline, the Regulation on Supply of Pharmaceuticals from Abroad ("Regulation") was published in the Official Gazette dated 3 February 2023 and numbered 32093. The Guideline on Supply of Pharmaceuticals from Abroad ("Guideline"), which contains the guiding provisions regarding the implementation of the Regulation, was once again updated on 22 September 2023, after being updated in April.
Dicle Doğan
Fatma Sevde Tan
20.12.2023

Healthcare Regulation 2024 in Turkey - Part 2

The Ministry of Health (MoH) is the main body in charge of health services in Türkiye. It regulates all healthcare institutions in the country, which includes patient care facilities such as hospitals, clinics and diagnostic centres and the practice of medical and other health professions. The Turkish Medicines and Medical Devices Agency (Agency) is a regulatory agency of the government that acts as the highest sanitary authority in terms of medical safety on medicines, health products, cosmetics and personal care products.
Özge Atılgan Karakulak
Dicle Doğan
Fatma Sevde Tan
Beste Turan
05.10.2023
Load More
Ready to stay ahead of the curve?
Share your interest anonymously and let us guide you through the informative articles on the hottest legal topics.
|
Successful Your message has been sent